Canada Life’s Acadia Pharmaceuticals ACAD Stock Holding History

Canada Life’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.3M	Sell	103,314 -3,655	-3%	-$87.3K	﹤0.01%	1108
2025 Q4	$2.86M	Sell	106,969 -16,277	-13%	-$389K	0.01%	1010
2025 Q3	$2.63M	Buy	123,246 +2,131	+2%	+$50.4K	﹤0.01%	1107
2025 Q2	$2.61M	Sell	121,115 -2,063	-2%	-$38.3K	﹤0.01%	1083
2025 Q1	$2.04M	Buy	123,178 +87,124	+242%	+$1.58M	﹤0.01%	1182
2024 Q4	$661K	Hold	36,054	–	–	﹤0.01%	1583
2024 Q3	$556K	Sell	36,054 -3,712	-9%	-$61.9K	﹤0.01%	1660
2024 Q2	$647K	Hold	39,766	–	–	﹤0.01%	1618
2024 Q1	$735K	Hold	39,766	–	–	﹤0.01%	1580
2023 Q4	$1.24M	Buy	39,766 +2,926	+8%	+$69.9K	﹤0.01%	1438
2023 Q3	$767K	Buy	36,840 +3,174	+9%	+$86.2K	﹤0.01%	1573
2023 Q2	$812K	Buy	33,666 +1,422	+4%	+$31.6K	﹤0.01%	1555
2023 Q1	$608K	Sell	32,244 -830	-3%	-$15.8K	﹤0.01%	1657
2022 Q4	$529K	Buy	33,074 +13,255	+67%	+$207K	﹤0.01%	1705
2022 Q3	$324K	Buy	19,819 +13,314	+205%	+$216K	﹤0.01%	1764
2022 Q2	$92K	Hold	6,505	–	–	﹤0.01%	1933
2022 Q1	$168K	Hold	6,505	–	–	﹤0.01%	1902
2021 Q4	$151K	Hold	6,505	–	–	﹤0.01%	1929
2021 Q3	$109K	Hold	6,505	–	–	﹤0.01%	2036
2021 Q2	$159K	Sell	6,505 -1,805	-22%	-$40.7K	﹤0.01%	1983
2021 Q1	$213K	Buy	8,310 +481	+6%	+$21.2K	﹤0.01%	1934
2020 Q4	$417K	Hold	7,829	–	–	﹤0.01%	1796
2020 Q3	$323K	Hold	7,829	–	–	﹤0.01%	1785
2020 Q2	$378K	Hold	7,829	–	–	﹤0.01%	1761
2020 Q1	$334K	Hold	7,829	–	–	﹤0.01%	1705
2019 Q4	$332K	Buy	+7,829	New	+$341K	﹤0.01%	1817
2019 Q3	–	Sell	-14,526	Closed	-$387K	–	1118
2019 Q2	$387K	Buy	+14,526	New	+$371K	﹤0.01%	1853
2019 Q1	–	Sell	-14,758	Closed	-$230K	–	2555
2018 Q4	$230K	Buy	14,758 +2,969	+25%	+$57.7K	﹤0.01%	1894
2018 Q3	$245K	Hold	11,789	–	–	﹤0.01%	1925
2018 Q2	$180K	Hold	11,789	–	–	﹤0.01%	2000
2018 Q1	$265K	Hold	11,789	–	–	﹤0.01%	1875
2017 Q4	$354K	Hold	11,789	–	–	﹤0.01%	1821
2017 Q3	$451K	Hold	11,789	–	–	﹤0.01%	1747
2017 Q2	$328K	Hold	11,789	–	–	﹤0.01%	1799
2017 Q1	$404K	Hold	11,789	–	–	﹤0.01%	1758
2016 Q4	$342K	Hold	11,789	–	–	﹤0.01%	1773
2016 Q3	$374K	Hold	11,789	–	–	﹤0.01%	1736
2016 Q2	$381K	Buy	11,789 +2,494	+27%	+$83.5K	﹤0.01%	1713
2016 Q1	$260K	Hold	9,295	–	–	﹤0.01%	1159
2015 Q4	$332K	Hold	9,295	–	–	﹤0.01%	1032
2015 Q3	$308K	Hold	9,295	–	–	﹤0.01%	1022
2015 Q2	$388K	Hold	9,295	–	–	﹤0.01%	1075
2015 Q1	$302K	Hold	9,295	–	–	﹤0.01%	1129
2014 Q4	$294K	Hold	9,295	–	–	﹤0.01%	1118
2014 Q3	$231K	Hold	9,295	–	–	﹤0.01%	1165
2014 Q2	$209K	Buy	9,295 +6,000	+182%	+$125K	﹤0.01%	1113
2014 Q1	$80K	Hold	3,295	–	–	﹤0.01%	1521
2013 Q4	$83K	Buy	+3,295	New	+$77.7K	﹤0.01%	1486

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Canada Life's ACAD Position: Q1 2026 in Review

Canada Life reduced its Acadia Pharmaceuticals (ACAD) stake by 3.4% in Q1 2026, selling an estimated $87.3K and leaving 103,314 shares worth $2.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1108.

Canada Life first reported a position in ACAD in Q4 2013 and has held it in 48 quarters since. The position peaked at $2.86M in Q4 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Canada Life held 103,314 shares of Acadia Pharmaceuticals worth $2.3M as of Q1 2026.
Canada Life sold 3,655 Acadia Pharmaceuticals shares in Q1 2026, an estimated $87.3K.
Acadia Pharmaceuticals made up ﹤0.01% of Canada Life's portfolio in Q1 2026, its #1108 holding.
Canada Life first reported a position in Acadia Pharmaceuticals in Q4 2013 and has held it in 48 quarters since.
Canada Life's Acadia Pharmaceuticals position peaked at $2.86M in Q4 2025.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.